EPTIFIBATIDE for Cerebral artery occlusion: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 29 adverse event reports in the FDA FAERS database where EPTIFIBATIDE was used for Cerebral artery occlusion.
Most Reported Side Effects for EPTIFIBATIDE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Product use in unapproved indication | 61 | 13.2% | 0 | 1 |
| Thrombocytopenia | 58 | 12.6% | 0 | 24 |
| Drug ineffective | 39 | 8.4% | 9 | 22 |
| Off label use | 31 | 6.7% | 1 | 4 |
| Haemoglobin decreased | 30 | 6.5% | 3 | 15 |
| Haemorrhage | 28 | 6.1% | 5 | 7 |
| Vascular stent thrombosis | 19 | 4.1% | 0 | 16 |
| Condition aggravated | 14 | 3.0% | 7 | 10 |
| Gastrointestinal haemorrhage | 14 | 3.0% | 1 | 9 |
| Haematoma | 14 | 3.0% | 4 | 9 |
| Product use issue | 14 | 3.0% | 1 | 2 |
| Hypotension | 13 | 2.8% | 6 | 8 |
| Pulmonary alveolar haemorrhage | 13 | 2.8% | 6 | 7 |
| Subarachnoid haemorrhage | 13 | 2.8% | 3 | 7 |
| Haemoptysis | 12 | 2.6% | 2 | 7 |
Other Indications for EPTIFIBATIDE
Antiplatelet therapy (60)
Product used for unknown indication (57)
Acute myocardial infarction (36)
Thrombosis (26)
Coronary artery thrombosis (18)
Percutaneous coronary intervention (17)
Myocardial infarction (13)
Acute coronary syndrome (12)
Thrombosis in device (12)
Ischaemic stroke (11)